FY2028 Earnings Forecast for TSE:ONC Issued By HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – HC Wainwright boosted their FY2028 earnings per share estimates for Oncolytics Biotech in a research report issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.60 for the year, up from their prior estimate of $0.58. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Separately, Raymond James increased their price target on Oncolytics Biotech from C$3.00 to C$3.50 in a research note on Friday, September 20th.

Oncolytics Biotech Trading Down 2.1 %

TSE:ONC opened at C$1.38 on Friday. The firm has a market cap of C$106.07 million, a price-to-earnings ratio of -3.63 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The firm has a 50-day moving average price of C$1.50 and a two-hundred day moving average price of C$1.45. Oncolytics Biotech has a 52 week low of C$1.15 and a 52 week high of C$2.32.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.